Stocks · News reference

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

2026-10-26 13:03:16 UTC

Equillium, Inc. has initiated its Phase 1 clinical trial for EQ504, an investigational oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator, by dosing the first subject in Australia.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: fiscal.ai
Observed: 2026-10-26 13:03:16 UTC
Checked: 2026-10-26 13:04:08 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Benzinga2026-11-04 21:05:47 UTCBenzinga Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
ADMA ARQT CRIS CUE EQ
SEC EDGAR2026-10-26 21:09:21 UTCSEC EDGAR
8-K filing — Equillium, Inc. (EQ)
Filed: 2026-10-26 AccNo: 0001193125-26-432158 Size: 181 KB Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
EQ
Benzinga2026-10-12 12:29:04 UTCBenzinga Newsdesk
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
EQ
Benzinga2026-10-05 20:10:30 UTCBenzinga Newsdesk
Australia's Therapeutic Goods Administration Grants Equillium Human Research Ethics Committee Approval For Phase 1 Clinical Trial Of EQ504.
EQ
Benzinga2026-09-04 17:46:52 UTCBenzinga Newsdesk
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.
EQ
Benzinga2026-08-14 18:40:44 UTCBenzinga Newsdesk
Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.
EQ

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Connected Markets

Related Headlines

12 Health Care Stocks Moving In Wednesday's After-Market Session

8-K filing — Equillium, Inc. (EQ)

Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

Australia's Therapeutic Goods Administration Grants Equillium Human Research Ethics Committee Approval For Phase 1 Clinical Trial Of EQ504.

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium shares are trading higher after the company reported better-than-expected Q2 EPS results.